The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64

International Immunopharmacology

Volumn 6, Issue 7, 2006, Pages 1194-1203

  McCarthy, Desmond A ^a   Macey, Marion G ^b   Streetly, Matthew ^c   Schey, Stephen A ^c   Brown, K Alun ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Actimid; Adhesion molecules; Haematopoiesis; Neutrophils

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; CD11B ANTIGEN; CD64 ANTIGEN; CELL ADHESION MOLECULE; GAMMA INTERFERON; M PROTEIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; THALIDOMIDE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE;

ADULT; AGED; APOPTOSIS; BLOOD PLATELETS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHILS; RECEPTORS, IGG; THALIDOMIDE;

EID: 33646736537     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.03.001     Document Type: Article

References (58)

1. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 (1991) 699-703
2. + subset. J Exp Med 187 (1998) 1885-1892
3. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4 (2004) 314-322
4. Anderson K.C. Novel therapies for multiple myeloma. Br J Haematol 120 (2003) 10-17
5. Anderson K.C. The role of immunomodulatory drugs in multiple myeloma. Semin Hematol 40 (2003) 23-32
6. Richardson P., Hideshima T., and Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother 56 (2002) 115-128
7. Dredge K., Dalgleish A.G., and Marriott J.B. Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 14 (2003) 331-335
8. Schey S.A., Fields P., Bartlett J.B., Clarke I.A., Ashan G., Knight R.D., et al. Phase I study of an immunomodulatory thalidomide analogue, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22 (2004) 3269-3276
9. Richardson P., Jagannath S., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
10. Streetly M., Macey M.G., McCarthy D.A., Knight R., Fields P., Brown K.A., et al. Changes in neutrophil phenotype following the administration of CC-4047 (Actimid) to patients with multiple myeloma. Blood 102 (2003) 687
11. Streetly M., Gyertson K., Kazmi M., Zeldis J., and Schey S. Alternate day Actimid™ (CC-4047) is well tolerated and is active when used to treat relapsed/refractory myeloma. Blood 104 (2004) [Abstract 332]
12. Koh K.R., Janz M., Mapara M.Y., Lemke B., Stirling D., Dorken B., et al. Immunomoduulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood (2004) [Electronic publication ahead of print. Prepublished on August 3, 2004 as DOI 10.1182/blood-2004-03-0828]
13. Gardiner E.E., De Luca M., McNally T., Michelson A.D., Andrews R.K., and Berndt MC. Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. Blood 98 (2001) 1440-1447
14. Shebuski R.J., and Kilgore K.S. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 300 (2002) 729-735
15. Fadlon E., Vordermeier S., Pearson T., Mire-Sluis A.R., and Dumonde D.C. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 91 (1998) 266-274
16. Quershi S.S., Lewis S.M., Gant V.A., Treacher D., Davis B.H., and Brown K.A. Increased distribution of CD64 on blood polymorphonuclear cells from patients with systemic inflammatory response syndrome (SIRS). Clin Exp Immunol 125 (2001) 258-265
17. DeGaetano G., Cerletti C., and Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 29 (1999) 41-49
18. Hartz S., Menart B., and Tschoepe D. Leukocyte apoptosis in whole blood involves platelet-dependent coaggregation. Cytometry Part A 52A (2003) 117-121
19. Macey M.G., Azam U., McCarthy D.A., Webb L., Chapman E.S., Okrongly D., et al. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine and diyridamole (CTAD) for assessing platelet activation on the ADVIA 120 Hematology System. Clin Chem 48 (2002) 891-899
20. McCarthy D.A., and Macey M.G. A simple flow cytometric procedure for the determination of surface antigens on unfixed leucocytes in whole blood. J Immunol Methods 163 (1993) 155-160
21. Macey M.G., McCarthy D.A., Azam U., Milne T., Golledge P., and Newland A. Ethylenediaminetetraacetic acid plus citrate-theophylline-adenosine-dipyridamole (EDTA-CTAD): a novel anticoagulant for the flow cytometric assessment of platelet and neutrophil activation ex vivo in whole blood. Cytometry 51B (2003) 30-40
22. Törnquist L., Vartia P., and Vartia Y.O. How should relative changes be measured?. Am Stat 39 (1985) 43-46
23. Buckle A.M., and Hogg N. The effect of IFN-γ and colony-stimulating factors on the expression of neutrophil membrane receptors. J Immunol 143 (1989) 2295-2301
24. Ellis T.N., and Beaman B.L. Interferon-γ activation of polymorphonuclear neutrophil function. Immunology 112 (2004) 2-12
25. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-γ. Ann Rev Immunol 15 (1997) 749-795
26. Takeshita S., Nakatani Y., Takata H., Kawase I., Yoshioka S., and Yoshioka S. Interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) enhance lipopolysaccharide binding to neutrophils via CD14. Inflamm Res 47 (1998) 101-103
27. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., and Spriggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178 (1993) 669-674
28. Radsak M., Iking-Konert C., Stegmaier S., Andrassy K., and Hansch G.M. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology 101 (2000) 521-530
29. Iking-Konert C., Wagner C., Denefleh B., Hug F., Schneider M., Andrassy K., et al. Up-regulation of the dendritic cell marker CD83 on polymorphonuclear neutrophils (PMN): divergent expression in acute bacterial infections and chronic inflammatory disease. Clin Exp Immunol 130 (2002) 501-508
30. Yamashiro S., Wang J.-M., Yang D., Gong W.-H., Kamohara H., and Yoshimura T. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 96 (2000) 3958-3963
31. Aiba S., Manome H., Yoshino Y., and Tagami H. Alteration in the production of IL-10 and IL-12 and aberrant expression of CD23, CD83 and CD86 by monocytes or monocyte-derived dendritic cells from atopic dermatitis patients. Exp Dermatol 12 (2003) 86-95
32. Reinisch W., Lichtenberger C., Steger G., Tillinger W., Scheiner O., Gangl A., et al. Donor dependent, interferon-γ induced HLA-DR expression on human neutrophils in vivo. Clin Exp Immunol 133 (2003) 476-484
33. Juffermans N.P., Verbon A., Schultz M.J., Hack C.E., van Deventer S.J., Speelman P., et al. Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob Agents Chemother 45 (2001) 1547-1549
34. Neubert R., Nogueira A.C., and Neubert D. Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci 51 (1992) 2107-2116
35. Geitz H., Handt S., and Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31 (1996) 213-221
36. Elghetany M.T. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis 28 (2002) 260-274
37. Kurzrock R., Rosenblum M.G., Sherwin S.A., Rios A., Talpaz M., Quesada J.R., et al. Pharmacokinetics, single-dose tolerance, and biologic activity of recombinant gamma-interferon in cancer patients. Cancer Res 45 (1985) 2866-2872
38. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.-T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
39. Dredge K., Marriot J.B., Todryk S.M., Muller G.W., Chen R., Stirling D.I., et al. Protective antitumour immunity induced by a costimulatory thalidomide analogue in conjunction with whole tumour cell vaccination is mediated by increased Th1-type immunity. J Immunol 168 (2002) 4914-4919
40. Schafer P.H., Gandhi A.K., Loveland M.A., Chen R.S., Man H.-W., Schnetkamp P.P.M., et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305 (2003) 1222-1232
41. Corral L.G., and Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 58 (1999) 107-113
42. Teo S.K. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7 (2005) E14-E19
43. Ethuin F., Gerard B., Benna J.E., Boutten A., Gougereot-Pocidalo M.-A., Jacob L., et al. Human neutrophils produce interferon gamma upon stimulation by interleukin-12. Lab Invest 84 (2004) 1363-1371
44. Ma X., Chow J.M., Gri G., Carra G., Gerosa F., Wolf S.F., et al. The interleukin 12 p40 gene promoter is primed by interferon in monocytic cells. J Exp Med 183 (1996) 147-157
45. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
46. Watford W.T., Moriguchi M., Morinobu A., and O'Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14 (2003) 361-368
47. Raefsky E.L., Platanias L.C., Zoumbos N.C., and Young N.S. Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 135 (1985) 2507-2512
48. Aulitzky W.E., Aulitzky W., Gastl G., Lanske B., Reitter J., Frick J., et al. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J Interf Res 9 (1989) 425-433
49. Zeldis J.B., Schafer P.H., Bennett B.L., Mercurio F., and Stirling D.I. Potential new therapies for Waldenstrom's macroglobulinemia. Semin Oncol 30 (2003) 275-281
50. Crepaldi L., Gasperini S., Lapinet J.A., Calzetti F., Pinardi C., Liu Y., et al. Up-regulation of IL-10R1 expression is required to render human neutrophils fully responsive to IL-10. J Immunol 167 (2001) 2312-2322
51. Herra C.M., Keane C.T., and Whelan A. Increased expression of Fc gamma receptors on neutrophils and monocytes may reflect ongoing bacterial infection. J Med Microbiol 44 (1996) 135-140
52. Leino L., Sorvajarvi K., Katajisto J., Laine M., Lilius E.M., Pelliniemi T.T., et al. Febrile infection changes the expression of IgG Fc receptors and complement receptors in human neutrophils in vivo. Clin Exp Immunol 107 (1997) 37-43
53. Ng P.C., Li G., Chui K.M., Chu W.C., Li K., Wong R.P., et al. Neutrophil CD64 is a sensitive diagnostic marker for early-onset neonatal infection. Pediatr Res 56 (2004) 795-803
54. Takano K., Kaganoi J., Yamamoto K., Takahashi A., Kido T., and Sasada M. Rapid and prominent up-regulation of the high-affinity receptor for immunoglobulin G (Fc gamma RI) by cross-linking of beta 2 integrins on polymorphonuclear leukocytes. Int J Hematol 72 (2000) 48-54
55. Hoffmeyer F., Whitte K., and Schmidt R.E. The high affinity FcγRI on PMN: regulation of expression and signal transduction. Immunology 92 (1997) 544-552
56. Akerley W.L., Guyre P.M., and Davies B.H. Neutrophil activation through high affinity Fcγ receptor using a monomeric antibody with unique properties. Blood 77 (1991) 607-615
57. Klebanoff S.J., Olszowski S., Van W.C., Voorhis J.A., Ledbetter A.M., and Schlechte K.G. Effects of γ-interferon on human neutrophils: protection from deterioration on storage. Blood 80 (1992) 225-234
58. Cusumano V., Mancuso G., Genovese F., Delfino D., Beninati C., Losi E., et al. Role of gamma interferon in a neonatal mouse model of group B streptococcal disease. Infect Immun 64 (1996) 2941-2944